Catalyst Event

Eli Lilly and Co (LLY) · Other

From Akros SCHK HK-Global Quality Factor Index (ASHGQLT)

4/30/2026, 12:00:00 AM

OtherSentiment: Positive

The U.S. FDA proposed removing tirzepatide, the active ingredient in Mounjaro and Zepbound, from the bulk drug substances list on 2026-04-30, restricting compounded versions. This regulatory protection of market share is estimated to result in a >10% price impact.

Korean Translation

2026년 4월 30일, 미국 FDA가 티르제파티드를 대량 원료의약품 목록에서 제외 제안하여 복제약 제조를 제한함. 시장 점유율 보호 효과로 인해 10% 이상의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline